News articles about Smith & Nephew (NYSE:SNN) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Smith & Nephew earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.0254440190872 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Smith & Nephew (SNN) traded up $0.59 during trading hours on Tuesday, reaching $35.68. The company’s stock had a trading volume of 957,866 shares, compared to its average volume of 505,987. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.18 and a quick ratio of 1.08. Smith & Nephew has a 1 year low of $29.76 and a 1 year high of $40.43.

Several equities research analysts recently weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $45.00 price target on shares of Smith & Nephew in a report on Friday, January 5th. Morgan Stanley downgraded Smith & Nephew from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Finally, Zacks Investment Research downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Smith & Nephew has an average rating of “Hold” and a consensus target price of $44.00.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.